Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 2500 Value Index

06/25/2021 | 12:00am EDT

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 2500 Value Index


ę S&P Capital IQ 2021
All news about EPIZYME, INC.
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented Du..
AQ
09/14EPIZYME : Announces Data from TAZVERIK« (Tazemetostat) Clinical Programs to be Presented D..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/16EPIZYME, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhib..
AQ
08/10EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to ..
MT
08/10EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rati..
MT
08/10EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Than-Expected..
MT
08/09EPIZYME : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Financials (USD)
Sales 2021 53,4 M - -
Net income 2021 -225 M - -
Net cash 2021 96,4 M - -
P/E ratio 2021 -2,44x
Yield 2021 -
Capitalization 545 M 545 M -
EV / Sales 2021 8,41x
EV / Sales 2022 4,48x
Nbr of Employees 304
Free-Float 77,3%
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 5,33 $
Average target price 11,14 $
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Grant C. Bogle President, Chief Executive Officer & Director
Matthew E. Ros Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-50.92%559
GILEAD SCIENCES, INC.22.19%89 886
BIONTECH SE309.08%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS32.25%67 216
VERTEX PHARMACEUTICALS-22.31%48 018